Articles: 26.22 19 November 2015

Assessment and management of glucocorticoid-induced osteoporosis

Glucocorticoid-induced osteoporosis (GIO) is the most prevalent form of secondary osteoporosis; however, many patients taking glucocorticoids are still missing out on fracture risk assessments and boneprotection therapy. This article describes the clinical features, assessment and recommended management of GIO.
Assessment and management of glucocorticoid-induced osteoporosis

More details...

Generic drug pricing – is it becoming a runaway train?

The global pharmaceutical industry often struggles to convince the world at large that it is putting patients’ interests alongside those of its shareholders. In October, a Sunday Times investigation found some companies are increasing the cost of generic drugs by up to 2000 per cent, …

More details...

Management of chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality, and its management requires a multidisciplinary approach. This review discusses the diagnosis of COPD and the treatment options available.
Management of chronic obstructive pulmonary disease

More details...

Medicines reconciliation: a patient safety priority

Medicines reconciliation is critical to safe, effective patient care and was identified as a key priority in the recent NICE guidance on Medicines Optimisation. Here, Dr Shah and Dr Barnett provide advice on conducting a complete and accurate medicines reconciliation.
Medicines reconciliation a patient safety priority

More details...

New from NICE

Tolvaptan for treating autosomal dominant polycystic kidney disease Tolvaptan (Jinarc) is a selective vasopressin V2 antagonist, which reduces cell proliferation, cyst formation and fluid excretion, reducing kidney growth and protecting kidney function.
New from NICE

More details...

Prolonged-release budesonide for mild-to-moderate ulcerative colitis

Cortiment is a new multimatrix (MMX) prolongedrelease formulation of budesonide for the treatment of mild-to-moderate active ulcerative colitis, which releases budesonide at a controlled rate throughout the colon. Here, Steve Chaplin outlines the clinical trial data for its efficacy and Jonathan Digby-Bell discusses its place …

More details...

Web design and marketing agency Leamington Spa